Recent Hodgkin's Lymphoma News

FDA Approves Adcetris® in Combination with Chemotherapy for Previously Untreated Stage III or IV Classical Hodgkin Lymphoma

(March 22, 2018)

CancerConnect News: The U.S. Food and Drug Administration (FDA) has approved Adcetris (brentuximab vedotin) in combination with chemotherapy in adult patients with previously untreated Stage III or IV... Continue Reading


Addition of the Precision Cancer Medicine Adcetris Reduces the Risk of Treatment Failure in Advanced Hodgkin Lymphoma

(March 1, 2018)

CancerConnect News: Patients with advanced Hodgkin lymphoma (HL) who were treated with a multi-drug regimen that included the precision cancer medicine Adcetris (brentuximab vedotin) had a 23-percent reduction... Continue Reading


Duration of Blood Storage Does Not Affect Outcomes for Patients Requiring Blood Transfusions

(December 1, 2016)

The length of time that blood is stored prior to a blood transfusion, within normal ranges, does not appear to affect mortality among patients requiring transfusions. These results were recently published... Continue Reading


CAR Therapy Effective in Advanced Lymphoma

(June 20, 2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer... Continue Reading


Defitelio® Approved for Life-Threatening Complication of Stem Cell Transplant

(March 30, 2016)

The United States Food and Drug Administration (FDA) has approved Defitelio® (defibrotide sodium) for the treatment of hepatic veno-occlusive disease (VOD) following a stem cell transplant. Defitelio... Continue Reading


ADCETRIS® Provides High-Activity as Initial Therapy in Elderly with Hodgkin’s Lymphoma

(October 6, 2015)

The agent, ADCETRIS® (brentuximab vedotin), provides high anti-cancer activity as initial therapy in elderly patients who might not be able to tolerate standard therapy for treatment of Hodgkin’s lymphoma.... Continue Reading


Adcetris® after Stem Cell Transplant Improves Survival in Hodgkin’s Lymphoma

(April 28, 2015)

For patients with relapsed or refractory Hodgkin’s lymphoma (HL), treatment with Adcetris® (brentuximab vedotin) after autologous stem cell transplant may improve survival. The Lancet published these... Continue Reading


Keytruda PD-1 Immunotherapy Shows Promise in Hodgkin’s Lymphoma

(December 23, 2014)

The cancer immunotherapy strategy known as programmed cell death 1 (PD-1) has generated great excitement for its ability to help the immune system recognize and attack cancer. Now according to researchers... Continue Reading


PD-1 Immunotherapy Shows Promise in Hodgkin’s Lymphoma

(December 18, 2014)

The cancer immunotherapy strategy known as programmed cell death 1 (PD-1) has generated great excitement for its ability to help the immune system recognize and attack cancer. Now according to researcher... Continue Reading


Post-Transplant Adcetris® Improves Treatment of Hodgkin’s Lymphoma and is Likely to Become New Standard of Care

(December 12, 2014)

The use of post stem cell transplant (SCT) maintenance therapy with Adcetris® (brentuximab vedotin) significantly improved progression-free survival in Hodgkin’s Lymphoma (HL) according to the results... Continue Reading


Next Page »